Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 180

Similar articles for PubMed (Select 19671850)

1.

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.

Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR.

Clin Cancer Res. 2009 Aug 15;15(16):5216-23. doi: 10.1158/1078-0432.CCR-09-0802. Epub 2009 Aug 11. Erratum in: Clin Cancer Res. 2009 Nov 15;15(22):7110.

2.

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.

Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A.

Lung Cancer. 2014 Feb;83(2):168-73. doi: 10.1016/j.lungcan.2013.11.019. Epub 2013 Dec 1.

PMID:
24380695
3.

Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas.

Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, Dias-Santagata D, Yagi Y, Mark EJ, Iafrate AJ, Mino-Kenudson M.

Mod Pathol. 2012 Nov;25(11):1462-72. doi: 10.1038/modpathol.2012.109. Epub 2012 Jun 29.

4.

Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.

Pareja F, Crapanzano JP, Mansukhani MM, Bulman WA, Saqi A.

Cancer Cytopathol. 2015 Mar;123(3):162-70. doi: 10.1002/cncy.21507. Epub 2014 Dec 29.

PMID:
25557162
5.

Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.

Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, Kim HJ, Yoon H, Lee CT, Jheon S, Choe JY, Chung JH.

Lung Cancer. 2012 Jun;76(3):403-9. doi: 10.1016/j.lungcan.2011.11.008. Epub 2011 Nov 30.

PMID:
22129856
6.

Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.

Zhang YG, Jin ML, Li L, Zhao HY, Zeng X, Jiang L, Wei P, Diao XL, Li X, Cao Q, Tian XX.

PLoS One. 2013 May 31;8(5):e64821. doi: 10.1371/journal.pone.0064821. Print 2013.

7.

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.

Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC.

Ann Oncol. 2013 Sep;24(9):2364-70. doi: 10.1093/annonc/mdt220. Epub 2013 Jun 19.

8.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.

J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.

9.

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.

Kim H, Yoo SB, Choe JY, Paik JH, Xu X, Nitta H, Zhang W, Grogan TM, Lee CT, Jheon S, Chung JH.

J Thorac Oncol. 2011 Aug;6(8):1359-66. doi: 10.1097/JTO.0b013e31821cfc73.

PMID:
21587085
10.

Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.

Sholl LM, Weremowicz S, Gray SW, Wong KK, Chirieac LR, Lindeman NI, Hornick JL.

J Thorac Oncol. 2013 Mar;8(3):322-8. doi: 10.1097/JTO.0b013e31827db604.

11.

Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.

Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, Johnson MR, Wang X, Peterson LM, Halling KC, Oliveira AM, Aubry MC, Yi ES.

Hum Pathol. 2009 Aug;40(8):1152-8. doi: 10.1016/j.humpath.2009.01.012. Epub 2009 Apr 22.

PMID:
19386350
12.

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.

Salido M, Pijuan L, Martínez-Avilés L, Galván AB, Cañadas I, Rovira A, Zanui M, Martínez A, Longarón R, Sole F, Serrano S, Bellosillo B, Wynes MW, Albanell J, Hirsch FR, Arriola E.

J Thorac Oncol. 2011 Jan;6(1):21-7. doi: 10.1097/JTO.0b013e3181fb7cd6.

13.

Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.

Wang J, Dong Y, Cai Y, Zhou L, Wu S, Liu G, Su D, Li X, Qin N, Nong J, Jia H, Zhang Q, Mu J, Zeng X, Zhang H, Zhang S, Zhang Z.

J Cancer Res Clin Oncol. 2014 Mar;140(3):453-60. doi: 10.1007/s00432-014-1584-8. Epub 2014 Jan 18.

PMID:
24442099
14.

Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.

Proietti A, Alì G, Pelliccioni S, Lupi C, Sensi E, Boldrini L, Servadio A, Chella A, Ribechini A, Cappuzzo F, Miccoli M, Fontanini G.

Cancer Cytopathol. 2014 Jun;122(6):445-53. doi: 10.1002/cncy.21418. Epub 2014 Mar 19.

PMID:
24648382
15.

Comprehensive histologic analysis of ALK-rearranged lung carcinomas.

Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, Sekine I, Fukayama M, Shibata T, Furuta K, Tsuda H.

Am J Surg Pathol. 2011 Aug;35(8):1226-34. doi: 10.1097/PAS.0b013e3182233e06.

PMID:
21753699
16.

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.

Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA, Rodig SJ.

Am J Surg Pathol. 2013 Sep;37(9):1441-9. doi: 10.1097/PAS.0b013e3182960fa7.

17.

Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients.

Wang WY, Liang DN, Yao WQ, Wu WL, Li JN, Chen M, Liao DY, Zhang M, Li GD.

Hum Pathol. 2014 Jul;45(7):1414-22. doi: 10.1016/j.humpath.2014.02.015. Epub 2014 Mar 5.

PMID:
24775606
18.

Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.

Cabillic F, Gros A, Dugay F, Begueret H, Mesturoux L, Chiforeanu DC, Dufrenot L, Jauffret V, Dachary D, Corre R, Lespagnol A, Soler G, Dagher J, Catros V, Le Calve M, Merlio JP, Belaud-Rotureau MA.

J Thorac Oncol. 2014 Mar;9(3):295-306. doi: 10.1097/JTO.0000000000000072.

PMID:
24518086
19.

ROS1 rearrangements define a unique molecular class of lung cancers.

Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ.

J Clin Oncol. 2012 Mar 10;30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3.

20.

Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung.

Schildhaus HU, Deml KF, Schmitz K, Meiboom M, Binot E, Hauke S, Merkelbach-Bruse S, Büttner R.

Mod Pathol. 2013 Nov;26(11):1468-77. doi: 10.1038/modpathol.2013.95. Epub 2013 Jun 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk